Page 59 - Htain Manual
P. 59

T
                           here is an increasing interest in including patient-reported outcome measures

                           (PROs) in clinical studies specifically those in tandem with economic evaluations

                           or as part of an HTA. PROs include measures like patient satisfaction and their

               health-related quality of life (HRQoL) and these capture certain treatment effects that are not
               captured by the main clinical outcomes. Moreover, since quality-of-life (QoL) measures focus

               on treatment effects that primarily impact the patient’s well-being, their relevance becomes

               all the more important for HTA studies. QoL measures are thus divided into two categories.


                   •  Disease-specific, or condition-specific measures: These concentrate on the main QoL
                       impacts of a particular disease. E.g., the EORTC instrument for cancer, CatQuest for

                       Cataract

                   •  Generic measures: These do not focus on the impacts of a particular disease. Rather,
                       they consider a broad range of dimensions of quality of life that, in principle, could be

                       impacted  by  any  disease,  including  physical  function,  mental  well-being,  social

                       function, and pain. The most widely used measure of this type is the EQ5D (-3L or 5L)


               What is a good measure for health outcomes?

                       An important characteristic required for a measure of health is that it should be able

               to compare changes across diseases and interventions. Now, as a cost-effectiveness analysis
               looks to compare the costs and effects of alternative interventions for one disease it does beg

               the question; why is comparison important? Consider that there is one intervention with a

               higher cost but with better overall health outcomes as compared to other interventions. The
               dilemma that arises now is whether to invest in such an intervention or not? To decide one

               would need to know if the additional health benefits are large enough to merit the additional

               expense  that the  costlier  intervention  provides..  Thus,  even  though the  evaluation  might

               focus on a single disease, the resource allocation and service outcomes needs to be looked at

               with a comparative lens.

                       Another characteristic required is that the health measure have a scale with interval

               properties. The reason for this is that firstly, we need to know by how much the health change

               has occurred, be it for better or for worse. Secondly, these health changes need to be related

               to the monetary changes to be scaled either up or down. In this, the scale may be binary,
               ordinal or cardinal depending on the conditions and requirements of the study.




                                                           47
   54   55   56   57   58   59   60   61   62   63   64